DONGSUNG PHARMACEUTICAL CO.,LTD Logo

DONGSUNG PHARMACEUTICAL CO.,LTD

A Korean firm making pharmaceuticals, cosmetics, and popular hair care products for over 60 years.

002210 | KO

Overview

Corporate Details

ISIN(s):
KR7002210003
LEI:
Country:
South Korea
Address:
서울특별시 도봉구 도봉로 683 (방학동) 동성빌딩, 서울특별시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Dongsung Pharmaceutical Co., Ltd. is a Korean company engaged in the manufacture and distribution of pharmaceuticals, cosmetics, and hair care products, with a history of over 60 years. The company's portfolio includes both prescription (ETC) and over-the-counter (OTC) medicines, with notable products like the gastrointestinal drug 'Jeongro-hwan'. In the consumer sector, Dongsung is well-known for its 'Seven-Ait' hair dye brand and a diverse line of cosmetics. The company focuses on developing nature-friendly products and is also active in research areas such as photodynamic therapy.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-15 00:00
Post-Annual General Meeting Information
임시주주총회결과
Korean 19.0 KB
2025-09-10 00:00
Legal Proceedings Report
소송등의제기ㆍ신청(경영권분쟁소송)
Korean 9.7 KB
2025-08-26 00:00
Legal Proceedings Report
소송등의판결ㆍ결정
Korean 6.7 KB
2025-08-25 00:00
Legal Proceedings Report
소송등의판결ㆍ결정
Korean 5.4 KB
2025-08-19 00:00
Proxy Solicitation & Information Statement
[기재정정]의결권대리행사권유참고서류
Korean 109.6 KB
2025-08-18 00:00
Legal Proceedings Report
소송등의제기ㆍ신청(경영권분쟁소송)
Korean 6.8 KB
2025-08-14 00:00
Major Shareholding Notification
[기재정정]주식등의대량보유상황보고서(일반)
Korean 91.0 KB
2025-08-14 00:00
Major Shareholding Notification
[기재정정]임원ㆍ주요주주특정증권등소유상황보고서
Korean 27.7 KB
2025-08-14 00:00
Audit Report / Information
반기검토의견부적정또는의견거절
Korean 6.4 KB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 903.0 KB
2025-08-14 00:00
Regulatory News Service
상장적격성실질심사관련주요개선계획(자율공시)
Korean 3.9 KB
2025-08-13 00:00
Proxy Solicitation & Information Statement
[기재정정]의결권대리행사권유참고서류
Korean 79.7 KB
2025-08-13 00:00
Delisting Announcement
기타시장안내 (개선기간 부여 결정)
Korean 6.0 KB
2025-08-11 00:00
Pre-Annual General Meeting Information
[기재정정]주주총회소집결의
Korean 29.4 KB
2025-08-11 00:00
Proxy Solicitation & Information Statement
[기재정정]의결권대리행사권유참고서류
Korean 74.3 KB

Automate Your Workflow. Get a real-time feed of all DONGSUNG PHARMACEUTICAL CO.,LTD filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for DONGSUNG PHARMACEUTICAL CO.,LTD

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for DONGSUNG PHARMACEUTICAL CO.,LTD via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

LISATA THERAPEUTICS, INC. Logo
Oncology firm with a platform for more effective, targeted delivery of anti-cancer drugs.
United States of America
LSTA
LIXTE BIOTECHNOLOGY HOLDINGS, INC. Logo
Developing novel PP2A inhibitors to enhance cancer therapies and overcome treatment resistance.
United States of America
LIXT
Longeveron Inc. Logo
Develops cell therapies for Alzheimer's, aging frailty, and rare infant heart defects.
United States of America
LGVN
Lonza Group AG Logo
A leading CDMO for pharma, biotech & nutrition, providing end-to-end development & manufacturing.
Switzerland
LONN
Lyell Immunopharma, Inc. Logo
Develops durable CAR T-cell therapies for solid tumors & blood cancers by reprogramming T-cells.
United States of America
LYEL
Lyra Therapeutics, Inc. Logo
Developing localized, long-acting therapies for chronic rhinosinusitis (CRS).
United States of America
LYRA
Lytix Biopharma AS Logo
Develops oncolytic peptide immunotherapies that kill cancer and stimulate an anti-tumor response.
Norway
LYTIX
MaaT Pharma Logo
Developing gut microbiome therapies to improve survival for cancer patients.
France
MAAT
Mabion S.A. Logo
Global CDMO providing end-to-end services for developing and manufacturing complex biologic drugs.
Poland
MAB
MACROGENICS INC Logo
Biopharma firm developing innovative antibody-based therapeutics for cancer treatment.
United States of America
MGNX

Talk to a Data Expert

Have a question? We'll get back to you promptly.